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Abstract 
Background: Bhutan has made substantial progress in reducing malaria incidence. The national guidelines rec-
ommend chloroquine (CQ) and primaquine (PQ) for radical cure of uncomplicated Plasmodium vivax, but the local 
efficacy has not been assessed. The impact of cases imported from India on the genetic make-up of the local vivax 
populations is currently unknown.
Methods: Patients over 4 years of age with uncomplicated P. vivax mono-infection were enrolled into a clinical effi-
cacy study and molecular survey. Study participants received a standard dose of CQ (25 mg/kg over 3 days) followed 
by weekly review until day 28. On day 28 a 14-day regimen of PQ (0.25 mg/kg/day) was commenced under direct 
observation. After day 42, patients were followed up monthly for a year. The primary and secondary endpoints were 
risk of treatment failure at day 28 and at 1 year. Parasite genotyping was undertaken at nine tandem repeat markers, 
and standard population genetic metrics were applied to examine population diversity and structure in infections 
thought to be acquired inside or outside of Bhutan.
Results: A total of 24 patients were enrolled in the clinical study between April 2013 and October 2015. Eight 
patients (33.3 %) were lost to follow-up in the first 6 months and another eight patients lost between 6 and 
12 months. No (0/24) treatment failures occurred by day 28 and no (0/8) parasitaemia was detected following PQ 
treatment. Some 95.8 % (23/24) of patients were aparasitaemic by day 2. There were no haemolytic or serious events. 
Genotyping was undertaken on parasites from 12 autochthonous cases and 16 suspected imported cases. Diversity 
was high (HE 0.87 and 0.90) in both populations. There was no notable differentiation between the autochthonous 
and imported populations.
Conclusions: CQ and PQ remains effective for radical cure of P. vivax in Bhutan. The genetic analyses indicate that 
imported infections are sustaining the local vivax population, with concomitant risk of introducing drug-resistant 
strains.
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Background
More than 2.8 billion people are reported to be at risk of 
Plasmodium vivax infection worldwide [1, 2], the num-
ber of reported infections ranging from 19 to 240 mil-
lion cases each year [3]. As the incidence of Plasmodium 
falciparum decreases in many areas of Asia, P. vivax has 
emerged as the more prominent species. P. vivax exhib-
its important biological differences from P. falciparum, 
including the development of dormant liver stages and 
the emergence of gametocytes before the onset of clini-
cal symptoms [4]. These properties afford the parasite 
greater transmission potential relative to P. falciparum, 
posing a challenge to control efforts and rendering P. 
vivax highly prone to resurgence. Furthermore P. vivax 
also exhibits greater genetic diversity than P. falciparum 
[5–8], enhancing the potential for P. vivax strains with 
adaptive genetic backgrounds to emerge in response to 
environmental challenges, such as anti-malarial drugs or 
host immune pressure. The large burden of low density P. 
vivax infections presents a diagnostic challenge, further 
impeding containment efforts [9].
Bhutan has made remarkable progress in reducing the 
malaria burden in the country, with a significant decline 
in clinical cases from nearly 40,000 in 1994 to 436 in 
2010 [10]. The majority of the remaining malaria burden 
is caused by P. vivax, which accounts for over 60  % of 
cases [11]. The vector-borne disease control programme 
(VDCP) aims to eliminate malaria by 2018 and to obtain 
WHO certification by 2020. The main areas of contin-
ued transmission in Bhutan are the low-lying southern 
parts of the country bordering the Indian states of Assam 
and West Bengal. Cross-border movements are a major 
threat to malaria elimination in Bhutan [10, 12]. Cur-
rently the majority of malaria cases seen in Bhutan are 
thought to be imported cases [13], which could under-
mine local intervention efforts by increasing parasite 
population diversity and adaptation potential, as well as 
the risk of drug resistance spread and outbreaks in host 
populations with insufficient immunity against the new 
strains. The propensity for P. vivax isolates to lie dormant 
in the liver for weeks or months before relapsing greatly 
enhances the parasite’s ‘mobility’, compounding the risks 
of importation of this species. Diligent surveillance of 
imported infections and ongoing local parasite transmis-
sion dynamics are critical to the success of malaria elimi-
nation efforts. As demonstrated in other studies, parasite 
genotyping can provide useful insights in monitoring 
both local and imported infection during the pre-elimi-
nation phase [14].
To date, there has been no clinical-parasitological 
evidence of chloroquine-resistant P. vivax in Bhutan. 
However, given the accumulating reports of chloroquine-
resistant P. vivax in other parts of the world [15], there is 
a need for close and continuous monitoring of efficacy of 
chloroquine (CQ) against P. vivax in Bhutan.
Maintaining momentum in the late stages of malaria 
elimination becomes increasingly challenging as the 
numbers of clinical cases falls and the public health pri-
ority for malaria control activities declines. However, 
during this phase, informed decision-making on the opti-
mal cost-effective strategies is critical, and yet the clinical 
and molecular characterization of the parasite popula-
tion is rarely addressed. The current study was conducted 
to address these issues in a very low-endemic pre-elimi-
nation setting, assessing for the first time the efficacy of 
CQ plus primaquine (PQ) against uncomplicated vivax 
malaria in Bhutan, and gauging the transmission dynam-
ics of autochthonous and suspected imported cases in 
the local P. vivax population.
Methods
Study sites and participants
Bhutan is located in the eastern Himalaya region, encom-
passing an area of approximately 38,000  km2, and shar-
ing borders with China in the north and India in the 
south, west and east. The population size is estimated 
over 772,000 with a floating population (expatriates) 
of ~37,000 persons [16]. About 70  % of the population 
live in rural areas on subsistence farms. Malaria is sea-
sonal, coinciding with the monsoon season. Two spe-
cies of malaria parasites co-exist: P. falciparum and 
P. vivax. Reported mosquito vectors for these species 
include Anopheles pseudowillmori and Anopheles culici-
facies. Anopheles minimus, Anopheles fluviatilis and 
Anopheles dirus were present in the past, but have not 
been recorded in recent years. The incidence of malaria 
has declined sharply in Bhutan from 194 cases (annual 
parasite incidence (API): 0.4/1000 risk population) in 
2011 to 48 cases (API: 0.1/1000 risk population) in 2013. 
Among the districts that reported malaria cases in 2013, 
the majority (60  %) was reported in Sarpang district 
(API: 10/1000 risk population). The remaining cases 
were reported in S/jongkhar, Dagana and Samtse dis-
tricts, with API of 3, 2 and 1.5 per 1000 risk population, 
respectively.
The study was designed as a 1-year trial at 12 sentinel 
sites: eight health centres in Sarpang district and four 
other sites in Samtse, Dagana and Samdrup Jonghkar dis-
tricts. These sites were chosen based on the number of 
reported cases in 2011 and 2012. Due to low recruitment, 
the study period was extended for a further 16 months and 
the number of sites expanded to include 35 health centres 
across an additional four high-risk districts (Pemagatshel, 
Trongsa, Tsirang, Wangdiphodrang) (Fig. 1).
Patients presenting with signs and symptoms of 
malaria were screened for inclusion criteria and enrolled 
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in either the clinical study or the molecular survey, or 
both. Inclusion criteria for the clinical study were: age 
4  years or over, P. vivax mono-infection, axillary tem-
perature ≥37.5 °C or history of fever during the previous 
24  h, ability to swallow oral medication, and willing-
ness to comply with the study protocol for the duration 
of the study. Patients with signs of severe malaria [17], 
severe malnutrition, a past history of haemolyses, severe 
anaemia, haemoglobin (Hb) <7  g/dl, any other acute or 
chronic disease, regular medication, or known hyper-
sensitivity against the study drugs were excluded from 
the study. Pregnant patients (positive hCG test) or lac-
tating women were excluded from PQ treatment. As per 
national guidelines, no G6PD testing was done prior to 
PQ treatment.
Patients were categorized into Bhutanese nationals 
and non-Bhutanese nationals. Non-Bhutanese nation-
als included individuals residing in Bhutan temporar-
ily or day time workers who do not reside in Bhutan. As 
per the active malaria surveillance program conducted 
by the National Vector Borne Disease Control division, 
all microscopy-positive malaria cases were subjected to 
active investigation following the World Health Organiza-
tion recommendations. The patient’s residential address 
was recorded along with details on patient travel his-
tory to malaria-endemic areas during the prior 1 month. 
Reactive case detection was conducted within a 1  km 
radius from the residence of the malaria case. Searches 
were conducted for the presence of relevant vectors in 
the residential area and environmental risk assessment 
for vectors. If a case involved a Bhutanese national with 
no recent travel history to a malaria-endemic area or if 
reactive case detection revealed presence or absence 
of malaria cases in the area, the case was classified as 
autochthonous. If a case involved a Bhutanese national 
with recent travel history to a malaria-endemic area, and 
there was no record of malaria cases reported in the resi-
dential area in the prior 3 years and reactive case detec-
tion failed to identify any malaria cases in the area, the 
case was classified as imported. If a case involved a non-
Bhutanese national who had travelled to Bhutan recently 
and the patient’s work place in Bhutan had no record of 
malaria cases reported in the prior 3 years, and reactive 
case detection failed to identify any malaria cases among 
local population in the area, the case was classified as 
imported.
All patients screened for the clinical study were also 
screened for participation in the molecular study and 
were enrolled when P. vivax mono-infection was con-
firmed. Written informed consent from the patient or 
their guardian was obtained for both studies prior to 
enrolment.
Study design and treatment
The study was designed as an observational evalua-
tion of clinical and parasitological responses to directly 
observed CQ treatment. PQ treatment was delayed 
until day 28 to allow the assessment of CQ efficacy [15]. 
Fig. 1 Map of the study sites. Circles depict the 12 sentinel sites at which enrolment was conducted over the full duration ofthe study (old Site). 
Squares depict the additional 23 sites from which enrolment was startedeight months into the study (new Site)
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After enrolment, patients were seen on days 1 and 2 for 
CQ treatment, on day 3 and then on days 7, 14, 28, 35 
and 42. PQ was given from days 28 to 41 under direct 
observation in the community. After completion of PQ 
treatment, patients were followed monthly for 1 year. In 
addition after day 42, patients were telephoned each week 
to ask about fever or symptoms suggestive of recurrent 
malaria. Study participants received a standard course of 
CQ (target age based dosage corresponding to 10 mg/kg 
on days 0 and 1 and 5  mg/kg on day 2) and PQ (target 
age based dosage corresponding to 0.25  mg/kg/day) for 
14 days as per national guidelines (Additional file 1).
Clinical procedures
A standard physical examination was undertaken at base-
line (day 0 pre-dosing) and on days 1, 2, 3, 7, 14 and 28. 
A complete medical history and demographic informa-
tion were recorded at baseline and a capillary or venous 
blood sample taken for microscopy, Hb and molecular 
analyses. At each follow-up visit, any adverse events were 
documented, the axillary temperature was measured and 
a finger-prick blood sample collected for microscopy. Hb 
was measured using Hemocue™ (Angelholm, Sweden) on 
days 7, 14, 28, 35, 41 and on the last visit.
Laboratory procedures
Microscopy
Thick and thin blood films were examined by two quali-
fied microscopists who read the slides independently, 
and the parasitaemia was calculated by averaging the two 
counts. Blood smears with discordant results (differences 
between the two microscopists in parasite species or 
the density of parasitaemia >50 %) were re-examined by 
a third, independent microscopist from the VDCP, and 
parasite density was calculated by averaging the two clos-
est counts. Slides were declared negative when no para-
sites were seen in 200 high power fields.
Molecular assays
DNA was extracted from 200 µl of whole blood using the 
QIAamp DNA Blood mini kit (Qiagen) according to the 
manufacturer’s instructions. Plasmodium species were 
confirmed by PCR using the protocol described by Pad-
ley et al. [18] with the modification that each species was 
diagnosed in a separate (non-multiplex) assay. Genotyp-
ing was undertaken at nine previously described short 
tandem repeat (STR) markers: Pv3.27, msp1F3, MS1, 
MS5, MS8, MS10, MS12, MS16 and MS20 [19, 20]. These 
markers are included in a consensus panel selected by 
partners within the Vivax Working Group of the Asia 
Pacific Malaria Elimination Network (APMEN) [21]. In 
addition to the full spectrum of nine markers, sub-anal-
yses of population diversity and genetic differentiation 
were undertaken on a sub-set of five markers (MS1, 
MS5, MS10, MS12, MS20) defined as exhibiting bal-
anced diversity in a recent study [22]. The Pv3.27, MS16 
and msp1F3 loci were amplified using methods described 
previously [23]. The protocol for the remaining loci and 
the details of the primer sequences and chromosomal 
locations for each marker have been provided previously 
[23, 24]. The labelled PCR products were sized by dena-
turing capillary electrophoresis on an ABI 3100 Genetic 
Analyzer with GeneScan LIZ-600 (Applied Biosystems) 
internal size standards. Genotype calling was undertaken 
using GeneMapper Version 4.0. To reduce potential arte-
facts, an arbitrary fluorescent intensity threshold of 100 
relative fluorescence units was applied for peak detection. 
All electropherogram traces were additionally inspected 
manually. As in other APMEN P. vivax genotyping stud-
ies, minor alleles were only called if they had a minimum 
33 % height of the predominant allele [25].
Study endpoints
Parasite recurrence was defined as any parasitaemia 
with P. vivax detected by microscopy during the follow-
up period. The primary efficacy endpoint was the risk of 
recurrent parasitaemia by day 28 and the secondary effi-
cacy endpoints were the cumulative risk of recurrent par-
asitaemia by 12  months and the proportion of patients 
with detectable parasitaemia on days 1 and 2. Safety out-
comes were the type and number of adverse events and 
serious adverse events occurring during the entire fol-
low-up and the Hb profile.
Clinical statistical analyses
Clinical data were entered into an access database. All 
statistical analyses were undertaken using STATA 13 
(StatCorp, USA). The Mann–Whitney U test or Kruskal–
Wallis method were used for non-parametric compari-
sons, and Student’s t test for parametric comparisons. For 
categorical variables percentages and corresponding 95 % 
confidence intervals (95 % CI) were calculated using Wil-
son’s method. Proportions were examined using χ2 with 
Yates’ correction or Fisher’s exact test. The cumulative 
risk of failure was assessed by survival analysis using the 
Kaplan–Meier method. Patients lost to follow-up were 
censored on the last day of follow-up.
Population genetic analyses
An infection was defined as polyclonal if more than one 
allele was observed at one or more loci. The multiplicity 
of infection (MOI) for a given sample was defined as the 
maximum number of alleles observed at any of the loci 
investigated. With the exception of measures of poly-
clonality and MOI, only the predominant allele at each 
locus in each isolate was used for analysis [25].
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The expected heterozygosity (HE) was measured 









, where n is the number of 
isolates analysed and pi is the frequency of the ith allele 
in the population. The probability (P) that two unrelated 
parasites exhibited homologous genotypes (expected 
homozygosity) was calculated for each marker using the 
formula P  =  Σpi2, where pi is the frequency of the ith 
allele in the population [26]. Cumulative probabilities 
(πPi) of two unrelated parasites exhibiting homologous 
genotypes at multiple loci were calculated by multiplying 
P for the individual loci in question.
Multi-locus genotypes (MLGs) were reconstructed 
from the predominant allele at each locus in isolates with 
no missing data. Multi-locus linkage disequilibrium (LD) 
was measured by the standardized index of association 
(IAS) using the web-based LIAN 3.5 software [27]. The 
significance of the IASestimates was assessed using 10,000 
random permutations of the data. LD was assessed in 
(1) all samples, and (2) with repeated MLGs represented 
once.
The genetic relatedness between sample pairs was 
assessed by measuring the proportion of alleles shared 
between MLG pairs (ps). Using (1-ps) as a measure of 
genetic distance [28], an unrooted neighbour-joining tree 
[29] was generated with the ape package using R software 
[30]. The correlation between genetic and temporal dis-
tance was assessed using Mantel’s r-test with 10,000 per-
mutations using the ade4 package in R [31].
Ethical considerations
The study was approved by the Research Ethics Board 
of Health, at the Ministry of Health in Bhutan (REBH 
2012/031), and the Human Research Ethics Commit-
tee of the Northern Territory Department of Health and 
Menzies School of Health Research, Australia (HREC 
2012-1871). The study was registered at ClinicalTrial.gov 
with the registration number NCT01716260.
Results
Study profile and baseline characteristics
Between May 2013 and October 2015, a total of 28 patients 
were screened for enrolment, four of whom declined 
consent. Of the remaining 24 patients, adherence to fol-
low-up was achieved in 19 (79.2 %) patients at day 28, 16 
(66.6 %) at 6 months and 8 (33.3 %) at 12 months (Fig. 2).
The median age of the study population was 28  years 
(interquartile range (IQR) 23–43) and all but three were 
male (87.5  %). Bhutanese nationals accounted for 37.5  % 
(9/24) of participants and non-Bhutanese nationals for 
the remaining 62.5 % (Table 1). All non-Bhutanese nation-
als came from India. Bhutanese nationals had higher 
mean body temperature at enrolment (38.0 vs 36.9  °C, 
p = 0.036), higher parasite densities (1103 parasites/µl vs 
336 parasites/µl, p = 0.054) and lower Hb (10.07 vs 11.6 g/dl, 
p = 0.16) compared to non-Bhutanese patients. Compared 
to Bhutanese patients, non-Bhutanese  patients had a 
shorter mean follow-up time (352 days 95 % CI 342.1–361.9 
vs 176.8 days 95 % CI 90.6–263.0, p = 0.036). 
28 Screened 
4 with no consent
24 enrolled 
1 withdrawn from study on day 1
15 Lost to follow up
4 before day 28
3 between day 28 and month 6 
8 between month 6 and 12 
8 with full follow up for 12 months
Fig. 2 Flowchart of patients in the clinical study
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Treatment
One patient had an incomplete course of CQ after with-
drawing from the study on day 1. All the other 23 patients 
received a full course of CQ. Two patients vomited 
their CQ doses on day 0 and a further two on day 1 and 
received replacement doses; all tolerated their retreat-
ment dose. Nineteen patients still in the study on day 
28 received a course of PQ. One patient was mistakenly 
started on PQ treatment on day 21. All treatment was 
directly observed and all patients received a full course 
of PQ. The median total dose CQ received was 25.9 mg/
kg (IQR 23.4–29.7) with no patients receiving less than 
20  mg/kg. The median total dose of PQ was 3.7  mg/kg 
(IQR 3.3–4.8) with a range between 2.8 and 5.7 mg/kg.
Efficacy outcomes
There was no treatment failure by day 28 and no periph-
eral parasitaemia was detected during the remaining 
follow-up after PQ treatment. On day 1, 45.2 % (11/24) 
patients remained parasitaemic by microscopy, but on 
day 2 this had fallen to 4.4  % (1/23). All patients had 
cleared asexual and sexual forms of parasites by day 3 
(0/22).
Safety outcomes
The mean Hb at enrolment was 11.4  g/dl (95  % CI 
10.8–11.9) with no significant difference between base-
line and day 7. By day 28, before start of PQ, the Hb 
concentration had risen to 12.0 g/dl (95 % CI 11.1–12.9) 
and this did not change significantly after 14 days of PQ 
(mean 12.1 g/dl (95 % CI 11.3–12.8). The Hb did not fall 
by more than 25  %  from baseline in any of the patients 
and none required a blood transfusion. There was no dif-
ference between Bhutanese and non-Bhutanese patients 
regarding their Hb concentrations before or after PQ 
treatment. Two patients reported stomach pain on day 1, 
and another two reported nausea on the same day. Five 
patients complained of headache on days 1, 2, 3 and 7. 
No serious adverse events occurred.
Population diversity and structure
Baseline blood samples were available in 96  % (23/24) 
of patients enrolled in the clinical survey. An additional 
five patients with microscopy and PCR-positive P. vivax 
infection could not participate in the clinical survey but 
their specimens were used for parasite genotyping. Forty-
six percent (13/28) of the samples were autochthonous 
and 54 % (15/28) were classified as imported. Genotyping 
was successfully undertaken in all of these samples, with 
only two isolates failing at a single marker (MS20 locus 
in both cases). All markers, including the five ‘balanced’ 
markers had high diversity (HE range 0.85–0.97) (Addi-
tional file 2).
Six (21.4 %) infections demonstrated evidence of poly-
clonality, including five (38  %) autochthonous and one 
(7  %) imported case (Table  2). One of these polyclonal 
Table 1 Baseline characteristics of patients included in the clinical study
a Median and (IQR and range)
b Mean (95 % CI)
Baseline characteristics
Number of patients enrolled 24
Age (years)a 28 (IQR 23–43; range 14–71)
Weight (kg)a 54.5 (IQR 50.0–59.0; range 37–70.5)
Height (cm)a 159.0 (IQR 153.5–162.5; range 145–170)
Temperature (°C)b 37.3 (SD 1.2)
Male gender (%) 21 (87.5 %)
Fever or history of fever 24 (100 %)
Haemoglobin (g/dl)b 11.4 (95 % CI 10.8–11.9)
Geometric mean parasitaemia (µl−1) 660 (95 % CI 331–1315)
Number of patients with gametocytes (%) 13 (54.2 %)
Location
 District Sarpang 14 (58.3 %)
 District Wangdiphodrang 6 (25 %)
 Other districts 4 (16.7 %)
Ethnicity
 Bhutanese nationals 9 (37.5 %)
 Non-Bhutanese nationals residing in Bhutan 14 (58.3 %)
 Non-Bhutanese nationals not residing in Bhutan 1 (4.2 %)
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infections was highly complex, displaying multiple 
alleles at five out of the nine loci: the remaining five 
polyclonal infections displayed multiple alleles at just 
one locus, indicative of low complexity. In contrast, 
population diversity was high across all sites (mean HE 
0.91). Diversity levels were high in both the autochtho-
nous (mean HE 0.87) and the imported infections (mean 
HE 0.90). Diversity remained high (mean HE 0.89) for 
autochthonous (mean HE 0.85) and imported (mean HE 
0.89) cases when analysis was restricted to the five bal-
anced markers.
There was no notable separation between the Bhuta-
nese vs non-Bhutanese isolates in the neighbour-joining 
tree (Fig.  3). Four infections from three autochthonous 
cases from patients attending the Sarpang District hospi-
tal between 1 July and 16 August, 2014, all carried iden-
tical or near-identical infections (eight or nine shared 
major alleles). Further investigation of these cases 
revealed epidemiological links between three patients 
(all Bhutanese nationals), with two patients residing in 
the same household (A14003 and A14004) and the third 
patient (A14005) living in a neighbouring household. The 
fourth patient (A14006) was a non-Bhutanese patient 
with an autochthonous infection, who had no apparent 
epidemiological link to the other three patients. All other 
isolates exhibited lower genetic relatedness, sharing no 
more than four major alleles (range 0–4 shared alleles) 
with another isolate. The probability (p) that two unre-
lated parasites would exhibit homologous genotypes at all 
nine loci was 2 × 10−10. Aside from the four isolates with 
identical/highly related MLGs, there was no evidence of 
significant correlation between the distance in sampling 
date and the proportion of alleles shared between infec-
tions (Mantel r-test, r =  0.05, p =  0.139). LD was high 
in the autochthonous population (IAS  =  0.495, p  <  0.01) 
but dropped more than two-fold after adjustment for 
the repeated MLGs in the identical strains (IAS  =  0.179, 
p < 0.01) (Table 2). There was no evidence of statistically 
significant LD in the imported population (IAS = −0.029, 
p > 0.05).
Discussion
This study presents the first description of the genetic 
diversity and structure of the parasite population and 
the sustained efficacy of CQ and PQ against uncompli-
cated vivax malaria in Bhutan. The clinical and molecular 
features of the parasite population were gathered as the 
country enters the final stages of malaria elimination. In 
this very low endemic setting, over 60 % of the infections 
Table 2 Genetic diversity and structure in the Plasmodium vivax population
Circles depict the 12 sentinel sites at which enrolment was conducted over the full duration of the study (old Site). Squares depict the additional 23 sites from which 
enrolment was started 8 months into the study (new Site)
HE expected heterozygosity, LD linkage disequilibrium, IA 
S index of association
NS not significant (p > 0.05)
a Only samples with no missing data at all nine loci are included in the analyses (infections from 13 autochthonous and 13 imported cases)
b Unique set of multi-locus genotypes (11 autochthonous and 13 imported cases)
* 0.01 < p ≤ 0.05
** p ≤ 0.01
Infection origin % Polyclonal  
infections
MOI, mean,  
median (range)
HE, mean ± SE  
(range)
LD in all isolatesa, IA 
S LD in unique MLGsb, 
IA 
S
Autochthonous 38 % (5/13) 1.46, 1 (1–3) 0.87 ± 0.01(0.78–0.91) 0.495 ** 0.179**
Imported 7 % (1/15) 1.07, 1 (1–2) 0.90 ± 0.02 (0.81–0.98) −0.029NS −0.029NS
All 21.4 % (6/28) 1.25, 1 (1–3) 0.91 ± 0.01 (0.85–0.97) 0.158 ** 0.024**
Fig. 3 Unrooted neighbour-joining tree illustrating the genetic 
relatedness between Plasmodium vivax isolates from autochthonous 
and imported cases
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sampled originated from non-Bhutanese patients travel-
ling across the border from northern India. The results 
reveal extensive genetic diversity in the P. vivax popula-
tion, likely sustained by infections imported from India.
The Bhutanese treatment policy for P. vivax appears 
to be effective with rapid early parasite clearance and 
no recurrences observed by day 28 [15]. These findings 
are in line with data from other locations in this region 
where P. vivax remains sensitive to CQ [15].
No relapses were recorded over the subsequent year 
following administration of directly observed PQ. The 
one-year follow-up in the current study should have 
been adequate to have captured even late recurrences, 
as described in parts of northern India [32, 33]. Almost 
two-thirds of the patients dropped out before the end of 
the follow-up, partially caused by the long follow-up and 
the high proportion of non-Bhutanese nationals moving 
back or away from the study sites. Sixteen of 24 patients 
participated in the study after 6  months and a further 
eight patients dropped out before the final visit. Directly 
observed treatment of a 14  day PQ regimen compared 
to unobserved treatment might have contributed sig-
nificantly to the excellent efficacy outcomes that were 
observed and may be necessary to achieve radical cure, 
especially in pre-elimination settings [34–36].
Comparison of baseline data between Bhutanese 
nationals and non-Bhutanese nationals indicated a trend 
towards more symptomatic disease among the Bhuta-
nese patient population with significantly higher mean 
temperatures at enrolment and higher parasite densi-
ties, which may reflect differences in prior exposure 
and acquired immunity. Interestingly, no children pre-
sented at any of the participating health centres and the 
youngest patient enrolled in the study was 23 years old. 
This is in line with reports from India where the highest 
reported number of cases is among young adults, most 
likely attributable to young males being at greater risk of 
malaria from employment-seeking activities.
In many countries PQ roll-out is hampered by con-
cerns over drug-induced haemolyses in G6PD-deficient 
patients [37]. The current study followed national malaria 
treatment guidelines, which do not dictate that G6PD 
testing must be conducted prior to PQ administration. 
No haemolytic events were observed and the mean Hb 
was similar before and after PQ treatment. Although 
there have been no published studies of the G6PD preva-
lence in Bhutan, reports from neighbouring India suggest 
highly varying prevalence rates among different ethnic 
groups ranging from 2.3 to 27.0 % [38, 39].
Even though the study was carried out in a very low 
transmission area, the genetic diversity in both autoch-
thonous and imported P. vivax infections (HE 0.87–90) 
was high, comparable to high transmission regions of 
Southeast Asia and the Pacific [7, 40]. This pattern con-
trasts with trends observed in P. falciparum populations, 
where expected heterozygosity generally exhibits a posi-
tive correlation with endemicity [41]. A recent study in 
Sri Lanka, in the final stages of elimination, identified a 
similar paradox, with increasing diversity in the P. vivax 
population as local transmission levels declined [42], 
leading the authors to postulate that the high diversity 
was a consequence of the increasing predominance of 
imported infections. Considering the long and highly 
porous border between southern Bhutan and north-
ern India [10], and the capacity for P. vivax infections to 
spread undetected as dormant hypnozoites, it is highly 
probable that infections introduced from India sustain 
the high P. vivax diversity observed in the local Bhuta-
nese population. The autochthonous Bhutanese infec-
tions exhibited nearly as high diversity (HE 0.87) as those 
from imported infections (HE 0.90), and there was no 
notable genetic differentiation between these two groups. 
India currently has the highest burden of P. vivax infec-
tion in the world, thus presenting a potentially highly 
diverse reservoir of infection [43].
The genetic analyses also revealed evidence of local 
transmission events, reflected by four genetically identi-
cal autochthonous strains sourced from patients resid-
ing in the same district (Sarpang) and presenting at the 
local health facility between 1 and 46 days of one another. 
Based on the diversity observed at each of the loci, the 
probability that two unrelated infections would pre-
sent with the same genetic profile across all nine loci by 
chance alone was extremely low (p = 2 × 10−10). These 
results highlight the capacity of the local vector popula-
tion to sustain transmission within Bhutan despite best 
efforts in vector control, and thus underline the impor-
tance of maintaining diligent surveillance, especially at 
border areas, in the final stages of malaria elimination to 
prevent outbreaks.
The absence of LD (IAS  =  −0.029, p  >  0.05) in the 
imported P. vivax population is consistent with these infec-
tions having been sourced largely from a high transmission 
setting within which frequent recombination between 
genetically distinct parasites breaks down LD. After adjust-
ing for the identical strains, LD in the autochthonous 
population declined more than two-fold but remained sig-
nificant (IAS = 0.179, p < 0.01). Given the low reported inci-
dence of P. vivax infection in Bhutan and low complexity 
of infections, it is likely that the local levels of LD reflect 
a complex combination of both local transmission, with a 
degree of inbreeding, and importation of a diverse array of 
infections. However, high rates of asymptomatic and sub-
patent infections will also sustain local transmission and 
parasite diversity; further studies are required to assess the 
depth of this hidden reservoir of infection.
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Previous APMEN studies using the same markers and 
methodologies have documented polyclonality rang-
ing from 3  % in South Korea, 4–12  % in Central China 
[44], 26 % in Sabah, Malaysia [23], 30 % in pre-elimina-
tion settings in the Solomon Islands [5], 23–70 % across 
a range of low to high endemic settings in Indonesia [7], 
and 8–67 % across a range of endemic settings in south-
ern Ethiopia [43]. The prevalence of polyclonal infec-
tions in Bhutan (21  % across national and non-national 
infections) was comparable to other low endemic sites 
in Sabah, the Solomon Islands and Indonesia. Similar to 
previous observations in Sabah, the complexity of the 
majority (5/6) of polyclonal infections in Bhutan was low, 
with only 1/9 markers exhibiting multiple alleles, indica-
tive of high relatedness between the clones. The patterns 
of complexity of infection observed in Bhutan likely 
reflect a combination of factors, including local transmis-
sion intensity, imported infections, diversity, and relapse 
dynamics.
The small sample size in Bhutan highlights the chal-
lenges for surveillance of the declining symptomatic ill-
ness as a country moves towards malaria elimination 
within its borders. At the end stages of elimination, 
selective drug pressure increases often resulting in the 
residual parasite population being the most drug resist-
ant [45]. In this scenario traditional clinical study designs 
may no longer be appropriate or feasible and innovative 
approaches are needed. The modest sample size of the 
present study also posed a challenge for the population 
genetic analysis, requiring application of measures robust 
to the limited sample size. Population genetic studies of P. 
vivax have been undertaken in many geographic regions 
(review in [14]), but there is sparse representation from 
very low endemic settings. Despite the small sample 
size, the study presented provides an important oppor-
tunity to inform on the genetic make-up of the parasite 
in this endemic setting. Furthermore, this study repre-
sents a high proportion of the Bhutanese P. vivax popula-
tion associated with symptomatic illness, accounting for 
57.4 % (31/54) of all reported cases in Bhutan during the 
study period.
Conclusions
In summary, this study demonstrates that supervised 
treatment with CQ plus 14  days of PQ remains highly 
effective at treating blood stage P. vivax infection and 
preventing relapse in uncomplicated patients in Bhutan. 
Over half of the cases presenting at the local health facili-
ties were visiting patients from India and, in conjunction 
with the genetic analyses, highlight that local transmis-
sion is being sustained primarily by importation of para-
sites from neighbouring countries. The risk that these 
imported infections could introduce drug-resistant para-
sites demands continued surveillance of the Bhutanese P. 
vivax and P. falciparum populations.
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